BIOLIFE SOLUTIONS INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
BLFS$38.61+3.5%Stored close · as of Oct 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
| (In thousands, except share data) | Series APreferredStockShares | Series APreferredStockAmount | CommonStockShares | CommonStockAmount | AdditionalPaid-inCapital | AccumulatedOtherComprehensiveLoss | AccumulatedDeficit | TotalShareholders’Equity |
|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2020 | — | $— | 33,039,146 | $33 | $302,598 | $— | $(98,202) | $204,429 |
| Stock issued as consideration in GCI acquisition | — | — | 6,636,470 | 7 | 232,734 | — | — | 232,741 |
| Stock issued as consideration in Sexton acquisition | — | — | 530,502 | — | 31,977 | — | — | 31,977 |
| Fees incurred for registration filings | — | — | — | — | (186) | — | — | (186) |
| Stock-based compensation | — | — | — | — | 13,956 | — | — | 13,956 |
| Stock option exercises | — | — | 869,065 | 1 | 1,417 | — | — | 1,418 |
| Cashless exercise of 79,100 warrants | — | — | 70,030 | — | 2,901 | — | — | 2,901 |
| Stock issued – on vested RSAs | — | — | 672,290 | 1 | — | — | — | 1 |
| Foreign currency translation | — | — | — | — | — | (282) | — | (282) |
| Net loss | — | — | — | — | — | — | (8,908) | (8,908) |
| Balance, December 31, 2021 | — | — | 41,817,503 | 42 | 585,397 | (282) | (107,110) | 478,047 |
| Stock issued as consideration for SciSafe earnout | — | — | 64,130 | — | 817 | — | — | 817 |
| Fees incurred for registration filings | — | — | — | — | (131) | — | — | (131) |
| Stock-based compensation | — | — | — | — | 25,334 | — | — | 25,334 |
| Stock option exercises | — | — | 161,646 | — | 323 | — | — | 323 |
| Stock issued – on vested RSAs | — | — | 788,952 | 1 | (1) | — | — | — |
| Other comprehensive loss | — | — | — | — | — | (397) | — | (397) |
| Net loss | — | — | — | — | — | — | (139,805) | (139,805) |
| Balance, December 31, 2022 | — | — | 42,832,231 | 43 | 611,739 | (679) | (246,915) | 364,188 |
| Stock issued as consideration for SciSafe earnout | — | — | 116,973 | — | 2,263 | — | — | 2,263 |
| Fees incurred for registration filings | — | — | — | — | (132) | — | — | (132) |
| Stock-based compensation | — | — | — | — | 31,670 | — | — | 31,670 |
| Stock option exercises | — | — | 239,043 | — | 507 | — | — | 507 |
| Stock issued – on vested RSA units | — | — | 1,267,837 | 1 | (1) | — | — | — |
| Settlement of Global Cooling escrow | — | — | (216,024) | — | (5,115) | — | — | (5,115) |
| Common stock shares issued | — | — | 927,165 | 1 | 10,374 | — | — | 10,375 |
| Other comprehensive loss | — | — | — | — | — | 334 | — | 334 |
| Net loss | — | — | — | — | — | — | (66,427) | (66,427) |
| Balance, December 31, 2023 | — | $— | 45,167,225 | $45 | $651,305 | $(345) | $(313,342) | $337,663 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.